Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
Jeanne Lenzer, Shannon Brownlee
Abstract
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory panellists who recommended approval. <b>Jeanne Lenzer</b> and <b>Shannon Brownlee</b> report
Topics & Concepts
DrugDrug approvalMedicinePharmacologyPharmaceutical industry and healthcarePharmaceutical Economics and PolicyHealth Systems, Economic Evaluations, Quality of Life